Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study

Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical therapeutics 2009-11, Vol.31 (11), p.2744-2754
Hauptverfasser: Li, Xiang-Yang, PhD, Gao, Fen, MS, Li, Zhan-Quan, MS, Guan, Wei, MS, Feng, Wei-Li, BS, Ge, Ri-Li, MD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2754
container_issue 11
container_start_page 2744
container_title Clinical therapeutics
container_volume 31
creator Li, Xiang-Yang, PhD
Gao, Fen, MS
Li, Zhan-Quan, MS
Guan, Wei, MS
Feng, Wei-Li, BS
Ge, Ri-Li, MD
description Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N4 -acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P < 0.001). The binding of su
doi_str_mv 10.1016/j.clinthera.2009.11.019
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733866888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0149291809004093</els_id><sourcerecordid>733866888</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-3b73fe4a07cc54531233dee64ae3f420fbdfc79c7e587dd5579e89fad139f3ba3</originalsourceid><addsrcrecordid>eNqNks2O0zAUhSMEYsrAK4AlhNhMih0njc0Cqar4k0ZiAUjsLMe5mbjj2BnbKVNemNfAUctUzIrVlazvHN-fk2UvCF4STFZvtktltI09eLksMOZLQpaY8AfZgrCa54SUPx5mC0xKnhecsLPsSQhbjDHlVfE4OyswITj5LLLfGzeM0uvgLHIdSo5o7KUfpHLX2kLUKszvYTKdHCD27lb-cgaQtmiQqao-UQHQzpnJRgAfkIzIuJ9Imqjj1AKStkVSTREQ3I4uTB5QdKjXV_2J2SXhFNI3zRZUDMjonbZXyd07q5U0Zj_b_qN5i9ap5RFsbmQD5gIpZ6N3xkB7gUbvwpic9A5QSPT-afaokybAs2M9z75_eP9t8ym__PLx82Z9mauS0ZjTpqYdlBLXSlVlRUlBaQuwKiXQrixw17SdqrmqoWJ121ZVzYHxTraE8o42kp5nrw--qYObCUIUgw4KjJEW3BRETSlbrRhjiXx5j9y6ydvUnCCYUlKxgvFE1QdKpYmCh06MXg_S7xMk5iiIrbiLgpijIAgRKQpJ-fzoPzUDtHe6v7dPwKsjIENaceelVTqcuKJguChnbn3gIO1tp8GLoDRYBa32acWidfo_mnl3z2Pm5stewx7CaXIRCoHF1zm5c3Axx7jEnNI_aAbylQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1033158289</pqid></control><display><type>article</type><title>Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Li, Xiang-Yang, PhD ; Gao, Fen, MS ; Li, Zhan-Quan, MS ; Guan, Wei, MS ; Feng, Wei-Li, BS ; Ge, Ri-Li, MD</creator><creatorcontrib>Li, Xiang-Yang, PhD ; Gao, Fen, MS ; Li, Zhan-Quan, MS ; Guan, Wei, MS ; Feng, Wei-Li, BS ; Ge, Ri-Li, MD</creatorcontrib><description>Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N4 -acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P &lt; 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group ( P &lt; 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t½ , 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT0–48 ), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (ke ), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours−1 ; AUC0–48 , 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- ( P &lt; 0.05) and chronic-exposure ( P &lt; 0.001) groups, respectively, than in the low-altitude group. AUC0–48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P &lt; 0.05). Conclusion: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2009.11.019</identifier><identifier>PMID: 20110016</identifier><language>eng</language><publisher>Bridgewater, NJ: EM Inc USA</publisher><subject>Altitude ; Anti-Infective Agents - administration &amp; dosage ; Anti-Infective Agents - pharmacokinetics ; Biological and medical sciences ; Biotransformation ; Blood ; Blood Chemical Analysis ; Blood Proteins - metabolism ; China ; Cytochrome ; Drugs ; Erythrocytes - metabolism ; healthy volunteers ; high altitude ; Humans ; Hypoxia ; Hypoxia - metabolism ; Internal Medicine ; Male ; Medical Education ; Medical sciences ; Metabolism ; Metabolites ; Pharmacokinetics ; Pharmacology. Drug treatments ; Prospective Studies ; Protein Binding ; sulfamethoxazole ; Sulfamethoxazole - administration &amp; dosage ; Sulfamethoxazole - analogs &amp; derivatives ; Sulfamethoxazole - blood ; Sulfamethoxazole - pharmacokinetics ; Young Adult</subject><ispartof>Clinical therapeutics, 2009-11, Vol.31 (11), p.2744-2754</ispartof><rights>Excerpta Medica Inc.</rights><rights>2009 Excerpta Medica Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2009 Excerpta Medica Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-3b73fe4a07cc54531233dee64ae3f420fbdfc79c7e587dd5579e89fad139f3ba3</citedby><cites>FETCH-LOGICAL-c483t-3b73fe4a07cc54531233dee64ae3f420fbdfc79c7e587dd5579e89fad139f3ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0149291809004093$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22280246$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20110016$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Xiang-Yang, PhD</creatorcontrib><creatorcontrib>Gao, Fen, MS</creatorcontrib><creatorcontrib>Li, Zhan-Quan, MS</creatorcontrib><creatorcontrib>Guan, Wei, MS</creatorcontrib><creatorcontrib>Feng, Wei-Li, BS</creatorcontrib><creatorcontrib>Ge, Ri-Li, MD</creatorcontrib><title>Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N4 -acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P &lt; 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group ( P &lt; 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t½ , 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT0–48 ), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (ke ), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours−1 ; AUC0–48 , 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- ( P &lt; 0.05) and chronic-exposure ( P &lt; 0.001) groups, respectively, than in the low-altitude group. AUC0–48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P &lt; 0.05). Conclusion: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m.</description><subject>Altitude</subject><subject>Anti-Infective Agents - administration &amp; dosage</subject><subject>Anti-Infective Agents - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Biotransformation</subject><subject>Blood</subject><subject>Blood Chemical Analysis</subject><subject>Blood Proteins - metabolism</subject><subject>China</subject><subject>Cytochrome</subject><subject>Drugs</subject><subject>Erythrocytes - metabolism</subject><subject>healthy volunteers</subject><subject>high altitude</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Hypoxia - metabolism</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical Education</subject><subject>Medical sciences</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Protein Binding</subject><subject>sulfamethoxazole</subject><subject>Sulfamethoxazole - administration &amp; dosage</subject><subject>Sulfamethoxazole - analogs &amp; derivatives</subject><subject>Sulfamethoxazole - blood</subject><subject>Sulfamethoxazole - pharmacokinetics</subject><subject>Young Adult</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNks2O0zAUhSMEYsrAK4AlhNhMih0njc0Cqar4k0ZiAUjsLMe5mbjj2BnbKVNemNfAUctUzIrVlazvHN-fk2UvCF4STFZvtktltI09eLksMOZLQpaY8AfZgrCa54SUPx5mC0xKnhecsLPsSQhbjDHlVfE4OyswITj5LLLfGzeM0uvgLHIdSo5o7KUfpHLX2kLUKszvYTKdHCD27lb-cgaQtmiQqao-UQHQzpnJRgAfkIzIuJ9Imqjj1AKStkVSTREQ3I4uTB5QdKjXV_2J2SXhFNI3zRZUDMjonbZXyd07q5U0Zj_b_qN5i9ap5RFsbmQD5gIpZ6N3xkB7gUbvwpic9A5QSPT-afaokybAs2M9z75_eP9t8ym__PLx82Z9mauS0ZjTpqYdlBLXSlVlRUlBaQuwKiXQrixw17SdqrmqoWJ121ZVzYHxTraE8o42kp5nrw--qYObCUIUgw4KjJEW3BRETSlbrRhjiXx5j9y6ydvUnCCYUlKxgvFE1QdKpYmCh06MXg_S7xMk5iiIrbiLgpijIAgRKQpJ-fzoPzUDtHe6v7dPwKsjIENaceelVTqcuKJguChnbn3gIO1tp8GLoDRYBa32acWidfo_mnl3z2Pm5stewx7CaXIRCoHF1zm5c3Axx7jEnNI_aAbylQ</recordid><startdate>20091101</startdate><enddate>20091101</enddate><creator>Li, Xiang-Yang, PhD</creator><creator>Gao, Fen, MS</creator><creator>Li, Zhan-Quan, MS</creator><creator>Guan, Wei, MS</creator><creator>Feng, Wei-Li, BS</creator><creator>Ge, Ri-Li, MD</creator><general>EM Inc USA</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20091101</creationdate><title>Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study</title><author>Li, Xiang-Yang, PhD ; Gao, Fen, MS ; Li, Zhan-Quan, MS ; Guan, Wei, MS ; Feng, Wei-Li, BS ; Ge, Ri-Li, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-3b73fe4a07cc54531233dee64ae3f420fbdfc79c7e587dd5579e89fad139f3ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Altitude</topic><topic>Anti-Infective Agents - administration &amp; dosage</topic><topic>Anti-Infective Agents - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Biotransformation</topic><topic>Blood</topic><topic>Blood Chemical Analysis</topic><topic>Blood Proteins - metabolism</topic><topic>China</topic><topic>Cytochrome</topic><topic>Drugs</topic><topic>Erythrocytes - metabolism</topic><topic>healthy volunteers</topic><topic>high altitude</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Hypoxia - metabolism</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical Education</topic><topic>Medical sciences</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Protein Binding</topic><topic>sulfamethoxazole</topic><topic>Sulfamethoxazole - administration &amp; dosage</topic><topic>Sulfamethoxazole - analogs &amp; derivatives</topic><topic>Sulfamethoxazole - blood</topic><topic>Sulfamethoxazole - pharmacokinetics</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Xiang-Yang, PhD</creatorcontrib><creatorcontrib>Gao, Fen, MS</creatorcontrib><creatorcontrib>Li, Zhan-Quan, MS</creatorcontrib><creatorcontrib>Guan, Wei, MS</creatorcontrib><creatorcontrib>Feng, Wei-Li, BS</creatorcontrib><creatorcontrib>Ge, Ri-Li, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Xiang-Yang, PhD</au><au>Gao, Fen, MS</au><au>Li, Zhan-Quan, MS</au><au>Guan, Wei, MS</au><au>Feng, Wei-Li, BS</au><au>Ge, Ri-Li, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2009-11-01</date><risdate>2009</risdate><volume>31</volume><issue>11</issue><spage>2744</spage><epage>2754</epage><pages>2744-2754</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Abstract Background: Sulfamethoxazole is an antibacterial sulfonamide used primarily for the treatment of a wide variety of bacterial infections in combination with trimethoprim. Despite being used as prophylactic treatment for respiratory infections associated with high altitude, little information is available on the pharmacokinetic properties of sulfamethoxazole in subjects living at high altitude, especially in a Chinese population. Objective: This study was conducted to investigate the pharmacokinetics of sulfamethoxazole in healthy Chinese subjects after acute and chronic exposure to high altitude. Methods: An open-label, controlled, prospective study was conducted in healthy Chinese male volunteers. Sulfamethoxazole 1200 mg was administered orally to volunteers in 3 groups: those residing at low altitude (~400 m [~1300 ft]); these same volunteers after 16 hours (acute) of exposure to high altitude (~3780 m [~12,400 ft]); and a separate group of volunteers who had been living at high altitude (~3780 m) for ≥1 year (chronic). The phases of the low-altitude and acute-exposure groups were separated by a 1-week washout period. Blood samples were collected from an indwelling venous catheter into heparinized tubes before (baseline) study drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours after study drug administration. Sulfamethoxazole in whole blood, plasma, and plasma water, and its metabolite, N4 -acetyl-sulfamethoxazole, in plasma were determined by HPLC. Tolerability was determined using blood chemistry testing, continuous 12-lead ECG, and blood pressure monitoring. Results: A total of 23 healthy Chinese male volunteers living at low altitude (race, all Han Chinese; mean [SD] age, 20.4 [1.1] years [range, 19–24 years]; weight, 64.2 [5.9] kg [range, 56.0–75.0 kg]; and height, 172.1 [4.9] cm [range, 163.0–180.0 cm]) and 21 healthy Chinese male volunteers living at high altitude (race, all Han Chinese; mean [SD] age, 21.2 [1.3] years [range, 19–24 years]; weight, 62.4 [8.2] kg [range, 50.0–75.0 kg]; and height, 171.4 [5.8] cm [range, 162.0–182.0 cm]) were enrolled in the study; 20 from each group completed the study. Concentration of sulfamethoxazole in plasma water decreased significantly after exposure to high altitude; therefore, the protein binding was significantly higher in the acute- (80.4%) and chronic-exposure (72.5%) groups compared with the low-altitude group (65.7%; both, P &lt; 0.001). The binding of sulfamethoxazole to red blood cells was 6.0%, 6.9%, and 9.3% in the low-altitude, acute-, and chronic-exposure groups, respectively. The chronic-exposure group was 55% higher than the low-altitude group ( P &lt; 0.001). The following values were recorded in the low-altitude, acute-, and chronic-exposure groups after administration of sulfamethoxazole, respectively: mean (SD) t½ , 9.30 (1.11), 10.37 (0.88), and 11.15 (1.53) hours; mean residence time (MRT0–48 ), 12.06 (0.94), 13.15 (0.67), and 13.00 (1.01) hours; elimination rate constant (ke ), 0.076 (0.010), 0.067 (0.006), and 0.063 (0.009) hours−1 ; AUC0–48 , 1202.5 (238.3), 1416.3 (202.6), and 1298.5 (256.0) μ/mL/h; and clearance (CL), 1.01 (0.22), 0.83 (0.13), and 0.92 (0.22) L/kg/h. The t½ was 11.5% and 19.9% higher in the acute- and chronic-exposure groups, respectively, compared with the low-altitude group, and 7.5% higher in the chronic-exposure group than in the acute-exposure group. MRT was 9.0% and 7.8% higher in the acute- ( P &lt; 0.05) and chronic-exposure ( P &lt; 0.001) groups, respectively, than in the low-altitude group. AUC0–48 was 17.8% higher and CL was 17.8% lower in the acute-exposure group compared with the low-altitude group (both, P &lt; 0.05). Conclusion: This study found significant changes in the disposition of sulfamethoxazole in these healthy male Chinese subjects after either acute or chronic exposure to an altitude of ~3780 m in comparison to those residing at an altitude of ~400 m.</abstract><cop>Bridgewater, NJ</cop><pub>EM Inc USA</pub><pmid>20110016</pmid><doi>10.1016/j.clinthera.2009.11.019</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0149-2918
ispartof Clinical therapeutics, 2009-11, Vol.31 (11), p.2744-2754
issn 0149-2918
1879-114X
language eng
recordid cdi_proquest_miscellaneous_733866888
source MEDLINE; Elsevier ScienceDirect Journals
subjects Altitude
Anti-Infective Agents - administration & dosage
Anti-Infective Agents - pharmacokinetics
Biological and medical sciences
Biotransformation
Blood
Blood Chemical Analysis
Blood Proteins - metabolism
China
Cytochrome
Drugs
Erythrocytes - metabolism
healthy volunteers
high altitude
Humans
Hypoxia
Hypoxia - metabolism
Internal Medicine
Male
Medical Education
Medical sciences
Metabolism
Metabolites
Pharmacokinetics
Pharmacology. Drug treatments
Prospective Studies
Protein Binding
sulfamethoxazole
Sulfamethoxazole - administration & dosage
Sulfamethoxazole - analogs & derivatives
Sulfamethoxazole - blood
Sulfamethoxazole - pharmacokinetics
Young Adult
title Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T05%3A39%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20pharmacokinetics%20of%20sulfamethoxazole%20in%20male%20chinese%20volunteers%20at%20low%20altitude%20and%20acute%20exposure%20to%20high%20altitude%20versus%20subjects%20living%20chronically%20at%20high%20altitude:%20An%20open-label,%20controlled,%20prospective%20study&rft.jtitle=Clinical%20therapeutics&rft.au=Li,%20Xiang-Yang,%20PhD&rft.date=2009-11-01&rft.volume=31&rft.issue=11&rft.spage=2744&rft.epage=2754&rft.pages=2744-2754&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2009.11.019&rft_dat=%3Cproquest_cross%3E733866888%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1033158289&rft_id=info:pmid/20110016&rft_els_id=1_s2_0_S0149291809004093&rfr_iscdi=true